EquitiesIndia.com

Healthcare · Drug Manufacturers - General

Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Key metrics

Market Cap

₹40,556 cr

P/E Ratio

39.68x

P/B Ratio

20.78x

ROE

47.54%

ROCE

64.31%

Debt / Equity

0.01x

Net Margin

24.89%

Dividend Yield

175%

EPS

₹54.76

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 75.65%FII: 7.47%Public: 16.88%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Glaxosmithkline Pharmaceuticals Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.